Navigation

PRESS RELEASES

Search all of our press releases here.

Search
Generic filters

Try these: Jeff GalvinC. David PauzaHIVFDAAmerican Gene Technologies

American Gene Technologies Passes Major Milestone in Potential HIV Cure Clinical Trial with Third Patient Showing No Serious Adverse Effects (SAEs)

By AGT | Nov 9, 2021
Filed Under:

Press release also featured on:  CISION PRWeb ROCKVILLE, MD. (PRWEB) NOVEMBER 09, 2021 American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) overseeing the trial of AGT’s HIV gene therapy found no serious adverse events (SAEs) from the treatment for the third patient and voted unanimously to allow AGT’s HIV cure program to… [Read More]

American Gene Technologies Appoints Dr. Marcus A. Conant as Special Advisor to the CEO

By AGT | Oct 1, 2021
Filed Under:

This press release was also featured on GlobeNewswire Dr. Conant, one of the first HIV/AIDS treatment pioneers, strengthens AGT’s capacity to progress toward a functional cure October 01, 2021 13:25 ET | Source:  American Gene Technologies ROCKVILLE, Md., Oct. 01, 2021 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announces the appointment of Dr. Marcus A. Conant, a leading dermatologist in the U.S. and… [Read More]

American Gene Technologies HIV Cure Clinical Trial Shows Additional Progress with No Serious Adverse Events (SAEs)

By AGT | Sep 23, 2021
Filed Under:

American Gene Technologies (AGT), a clinical-stage biotechnology company, announced that the independent Data Safety and Monitoring Board (DSMB) in charge of the trial safety found no serious adverse events (SAEs) from the treatment for the second patient and voted unanimously to allow AGT’s HIV cure program to continue without modification. The third participant is expected to be infused by the first week… [Read More]

American Gene Technologies Appoints Dr. Robert R. Redfield as Special Advisor to the CEO

By AGT | Sep 15, 2021
Filed Under:

Dr. Redfield’s expertise in virology strengthens AGT’s capacity to develop innovative HIV treatments. American Gene Technologies (AGT) announces the appointment of Dr. Robert R. Redfield, former director of the Centers for Disease Control and Prevention (CDC) and co-founder of the Institute for Human Virology, as special advisor to AGT CEO Jeff Galvin. Dr. Redfield is well known for his decades… [Read More]

HIV Cure Program Releases Initial Clinical Trial Data

By AGT | Jul 16, 2021
Filed Under:

ROCKVILLE, MD, July 15, 2021 /Globe Newswire/ — American Gene Technologies (AGT) announced today that the Data and Safety Monitoring Board (DSMB) voted unanimously to continue AGT’s HIV cure program without modification, after safety analysis of the participant’s data revealed no adverse effects from the treatment. AGT’s Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV… [Read More]

First Infusion Press Release

AGT Announces Progress with HIV Cure Program, Phase 1 Clinical Trial

By AGT | May 27, 2021
Filed Under:

ROCKVILLE, MD, May 27, 2021 /PR Newswire/ — American Gene Technologies (AGT), a clinical-stage biotechnology company, announced treatment of the first participant in its Phase I clinical trial to evaluate safety of the cell and gene therapy product AGT103-T. Designated as the RePAIR trial (Restore Potent Antiviral Immune Responses, NCT04561258), participants are infused once with their own CD4 T cells… [Read More]

LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases

LGBT+ Investment Firm Gaingels Joins American Gene Technologies’ Mission to Cure HIV, and Other Serious Human Diseases

By AGT | Apr 14, 2021
Filed Under:

ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ – American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of… [Read More]

American Gene Technologies Announces First Trial Participant Enrolled in Phase 1 Study of AGT103-T Against HIV

By AGT | Nov 10, 2020
Filed Under:

ROCKVILLE, Md., Nov. 10, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) announced today that the first trial participant was enrolled in the Phase 1 trial of AGT103-T, a new cell and gene therapy for HIV disease. The first trial participant underwent leukapheresis, a procedure for obtaining concentrated white blood cells, which will be used for manufacturing the AGT103-T cell product. After manufacturing… [Read More]

American Gene Technologies to Present at 2020 Virtual Cell & Gene Meeting on the Mesa

By AGT | Oct 8, 2020
Filed Under:

ROCKVILLE, Md., Oct. 08, 2020 (GLOBE NEWSWIRE) — American Gene Technologies (AGT) a cutting-edge cell and gene therapy company in Rockville, Maryland announced today that CEO Jeff Galvin will present at the annual Cell & Gene Meeting on the Mesa. The meeting will be held virtually October 12-16. Galvin’s presentation will highlight the company’s technology, including AGT103-T, a therapeutic intended to cure HIV, which… [Read More]

FDA Approves American Gene Technologies (AGT) To Move Forward With Phase 1 Clinical Trial Of HIV Cure Program

By AGT | Aug 11, 2020
Filed Under:

ROCKVILLE, Md., Aug. 11, 2020 /PRNewswire/ — American Gene Technologies (AGT) announced today approval by the FDA (Food and Drug Administration) to begin Phase 1, the first human clinical trial for AGT’s lead HIV program. AGT will conduct its Phase 1 study at clinical sites in the Baltimore/D.C. area, and has named Washington Health Institute, University of Maryland, Institute of Human Virology and Georgetown… [Read More]

Subscribe to Press Release and News Updates

Subscribe to our press release and published article updates to be notified when we release new content!

Follow AGT on Social Media